Product: PD1 Antibody
Catalog: DF2943
Description: Rabbit polyclonal antibody to PD1
Application: WB
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Rabbit, Dog
Mol.Wt.: 32kDa, 50~100kD(Glycosylated); 32kD(Calculated).
Uniprot: Q15116
RRID: AB_2840927

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-2000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Rabbit(100%), Dog(100%)
Clonality:
Polyclonal
Specificity:
PD1 Antibody detects endogenous levels of total PD1.
RRID:
AB_2840927
Cite Format: Affinity Biosciences Cat# DF2943, RRID:AB_2840927.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CD279; CD279 antigen; hPD 1; hPD l; hPD-1; hSLE1; PD 1; PD-1; PD1; PDCD 1; PDCD1; PDCD1_HUMAN; Programmed cell death 1; Programmed cell death 1 protein; Programmed cell death protein 1; Protein PD 1; Protein PD-1; SLEB2; Systemic lupus erythematosus susceptibility 2;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Sequence:
MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Dog
100
Rabbit
100
Chicken
33
Sheep
0
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q15116 As Substrate

Site PTM Type Enzyme
N49 N-Glycosylation
N58 N-Glycosylation
N74 N-Glycosylation
N116 N-Glycosylation
S159 Phosphorylation
Y223 Phosphorylation
K233 Ubiquitination
Y248 Phosphorylation
S285 Phosphorylation

Research Backgrounds

Function:

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity).

The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.

PTMs:

Ubiquitinated at Lys-233 by the SCF(FBXO38) complex, leading to its proteasomal degradation. Ubiquitinated via 'Lys-48'-linked polyubiquitin chains.

Tyrosine phosphorylated at Tyr-223 (within ITIM motif) and Tyr-248 (ITSM motif) upon ligand binding. Phosphorylation at Tyr-248 promotes the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta.

N-glycosylation at Asn-58 consists of two N-acetylglucosamine units and one fucose. N-glycosylation does not affect binding to nivolumab drug.

Subcellular Location:

Cell membrane>Single-pass type I membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Monomer. Interacts with CD274/PDCD1L1. Interacts with CD273/PDCD1LG2 (By similarity). Interacts with FBXO38; leading to ubiquitination and degradation of PDCD1 by the proteasome.

Research Fields

· Environmental Information Processing > Signaling molecules and interaction > Cell adhesion molecules (CAMs).   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

References

1). SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer. Frontiers in Oncology, 2020 (PubMed: 32528869) [IF=4.7]

Application: IHC    Species: human    Sample: breast cancer

FIGURE 5 | Correlation between sirtuin (SIRT)7 expression and immune infiltration levels of M1 macrophages and T cell exhaustion in breast cancer-luminal.. (B) Tumor infiltration of M1 macrophages and T cell exhaustion in breast cancer-luminal. The expression of SIRT7 (a: + + +, d: +). The expression of IRF5 (b: ++, e: –). The expression of PD1 (PDCD1) (c: + + +, f: +). The expression density of SIRT7, PD1, and IRF5 in breast cancer tissue was quantitated by scoring staining intensity,including negative (–) and weak (+) staining, moderate (++) and strong (+ + +) staining, respectively

2). PD-1-Positive Tumor-Associated Macrophages Define Poor Clinical Outcomes in Patients With Muscle Invasive Bladder Cancer Through Potential CD68/PD-1 Complex Interactions. Frontiers in Oncology, 2021 (PubMed: 34079767) [IF=4.7]

Application: IHC    Species: Human    Sample: TAMs

FIGURE 3 | (A) Immunohistochemical staining of PD-1-positive TAMs (red arrow), PD-1-negative TAMs (purple arrow), strong PD-L1 and weak PD-L1 expression. (B) Kaplan-Meier analysis of OS in patients with MIBC with PD-1-positive TAMs in the Shanghai General Hospital cohort. (C) Kaplan-Meier analysis of DFS in patients with MIBC with PD-1-positive TAMs in the Shanghai General Hospital cohort. (D) PD-1-positive TAMs showed less CD8-postive T cells nearby. ***p < 0.001 (Student’s t-test). (E) The number of PD-1-positive TAMs showed a correlation with PD-L1 expression in the Shanghai General Hospital cohort.

Application: IF/ICC    Species: Human    Sample: TAMs

FIGURE 4 | (A) Immunofluorescence staining confirmation for the appearance of PD-1-positive TAMs. (B) mRNA expression of CD68 showed a correlation with PD-1 expression in the TCGA cohort. (C) mRNA expression of CD68 showed a correlation with PD-L1 expression in the TCGA cohort.

3). PD-1 inhibitor induces myocarditis by reducing regulatory T cells, activating inflammatory responses, promoting myocardial apoptosis and autophagy. CYTOKINE, 2022 (PubMed: 35691121) [IF=3.8]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.